View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Verastem Inc: 3 directors

Three Directors at Verastem Inc sold/sold after exercising options 20,800 shares at 10.000USD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...

Merck KGaA: Annual update

Our credit view of this issuer reflects its track record of conservative financial policies and solid cash flow generation, constrained by its currently weak late-stage pipeline.

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Merck KGaA - INITIATION - Springing to Life (BUY, TP EUR150, 54pgs)

We initiate with a BUY as we show why the SpringWorks deal transforms the outlook for Merck KGaA. We show it could be 17% accretive to group EPS by 2030, driven by our ~50% above consensus sales for Gomekli & Ogsiveo and we assume significant synergies. Moreover, we show that Healthcare sales now grow 5% CAGR to 2030 & EBITDA grows 8%. This is highly likely to drive a re-rating in the Merck KGaA shares in our view. There is upside potential from label expansions. Our view on the Life Science too...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch